Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a stricter glucose goal improve diabetes control in children?

NCT ID NCT07376850

Disease control Sponsor: University Hospital, Motol Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will enroll 120 children and teens with type 1 diabetes who use automated insulin pumps. Participants will be randomly assigned to follow either the standard blood sugar target (70-180 mg/dL) or a tighter target (70-140 mg/dL) for 12 months. Researchers want to see if the tighter range leads to better overall glucose control without increasing low blood sugar episodes or stress on families.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Structured diabetes education on two different glucose targets (Time in Range vs. Time in Normal Glycemia)
What this could lead to
If successful, this could show that a tighter glucose target is safe and effective for children with type 1 diabetes, potentially updating clinical guidelines worldwide.
What could go wrong
This is a relatively small, early-stage study (120 participants) comparing two educational approaches, not testing a new drug or device. The tighter target may increase hypoglycemia risk or family stress without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of T1D per ADA criteria * Age 5.0-17.99 at the start of study * CGM use \>70% of the time during the month prior to enrollment * Maximum HbA1c of 86mmol/mol (10% in DCCT) Exclusion Criteria: * No concurrent illnesses impacting glycemia * No treatments impacting glycemia * Severe hypoglycemia documented in the 60 day period leading up to patient recruitment * Current participation in any other interventional study * Any significant diseases / conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise participant's safety * Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Diabetes (DM) Diabetes type 1

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of Warsaw

    Warsaw, Poland

  • Motol University Hospital

    Prague, Czechia

  • Schneider Children's Medical Center of Israel

    Petah Tikva, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.